Glucagon

1. Overview

Glucagon is a 29-amino acid peptide hormone produced by the alpha cells of the pancreatic islets of Langerhans that functions as the principal counter-regulatory hormone to insulin [3][6]. First identified in 1923 by Kimball and Murlin as a hyperglycemic contaminant in pancreatic extracts, the name "glucagon" derives from "glucose agonist," reflecting its primary role in raising blood glucose concentrations [1]. Its complete amino acid sequence was determined in 1957 by Bromer and colleagues at the Eli Lilly Research Laboratories [2].

Glucagon acts primarily on the liver through the Gs-coupled glucagon receptor (GCGR), a class B G-protein-coupled receptor, to stimulate hepatic glucose output via glycogenolysis and gluconeogenesis [4][5]. This counter-regulatory mechanism is essential for maintaining euglycemia during fasting and preventing life-threatening hypoglycemia. Beyond its metabolic role, glucagon exerts clinically useful effects on the heart (positive inotropy and chronotropy independent of beta-adrenergic receptors) and the gastrointestinal tract (smooth muscle relaxation), which underpin its therapeutic applications in poisoning management and diagnostic imaging [9][10][20].

Pharmacologically, glucagon has been available as an injectable medication since the 1960s. Traditional formulations required reconstitution from lyophilized powder immediately prior to use, a process that proved challenging for laypersons during hypoglycemic emergencies. Since 2019, a new generation of glucagon products has reached the market, including nasal glucagon (Baqsimi, Eli Lilly), ready-to-use liquid glucagon injection (Gvoke, Xeris Biopharma), and the stable glucagon receptor agonist analog dasiglucagon (Zegalogue, Zealand Pharma) [11][12][14]. These innovations have substantially improved the practicality of emergency hypoglycemia treatment.

Molecular Weight

3482.75 Da (C153H225N43O49S)

Sequence

29 amino acids: HSQGTFTSDYSKYLDSRRAQDFVQWLMNT

Half-life

8–18 min (IV), 26 min (IM), 42 min (SC), ~35 min (intranasal)

Receptor

Glucagon receptor (GCGR), class B GPCR, Gs-coupled

Routes

IM, SC, IV (injection); intranasal (Baqsimi)

FDA Status

Approved: hypoglycemia rescue and GI diagnostic aid

Source Cells

Alpha cells of pancreatic islets of Langerhans

2. Molecular Biology and Structure

Gene and Precursor Processing

Glucagon is encoded by the GCG gene (chromosome 2q24.2), which gives rise to a single mRNA transcript translated into the 180-amino acid precursor proglucagon [6][22]. The biological identity of the peptides produced from proglucagon depends on the tissue-specific expression of prohormone convertase enzymes:

• Pancreatic alpha cells express prohormone convertase 2 (PC2), which cleaves proglucagon to yield glucagon (positions 33–61 of proglucagon), glicentin-related pancreatic polypeptide (GRPP), and the major proglucagon fragment (MPGF) [6].
• Intestinal L cells and brainstem neurons express prohormone convertase 1/3 (PC1/3), which processes proglucagon into glucagon-like peptide-1 (GLP-1, positions 78–107), glucagon-like peptide-2 (GLP-2, positions 126–158), glicentin, and oxyntomodulin [6][22].

This tissue-specific differential processing of a single precursor is a remarkable example of post-translational regulation, producing hormones with distinct and in some cases opposing physiological effects from a shared gene product.

Primary Structure

Human glucagon is a single-chain, non-glycosylated polypeptide of 29 amino acid residues with the sequence:

H-His¹-Ser²-Gln³-Gly⁴-Thr⁵-Phe⁶-Thr⁷-Ser⁸-Asp⁹-Tyr¹⁰-Ser¹¹-Lys¹²-Tyr¹³-Leu¹⁴-Asp¹⁵-Ser¹⁶-Arg¹⁷-Arg¹⁸-Ala¹⁹-Gln²⁰-Asp²¹-Phe²²-Val²³-Gln²⁴-Trp²⁵-Leu²⁶-Met²⁷-Asn²⁸-Thr²⁹-OH

One-letter code: HSQGTFTSDYSKYLDSRRAQDFVQWLMNT

The molecular formula is C₁₅₃H₂₂₅N₄₃O₄₉S, with a monoisotopic molecular weight of 3482.75 Da [2]. The N-terminal region (residues 1–5) shares significant homology with GLP-1, GLP-2, GIP, secretin, and VIP, reflecting the evolutionary relationship within the secretin-glucagon peptide superfamily. The single methionine residue at position 27 renders the molecule susceptible to oxidative degradation, which contributes to the instability of glucagon in aqueous solution and the historical need for lyophilized formulations.

Three-Dimensional Structure and Receptor Binding

Glucagon adopts a largely alpha-helical conformation upon receptor binding. In solution, the peptide is relatively disordered, but it becomes structured upon interaction with the GCGR extracellular domain. The crystal structure of the human glucagon receptor (GCGR) was first resolved at 2.5 angstrom resolution in complex with the antagonist MK-0893 (PDB: 5EE7), and subsequent cryo-electron microscopy structures have captured the full-length glucagon-bound GCGR in complex with Gs protein (PDB: 6LMK) and Gi1 protein (PDB: 6LML) [7][8]. These structures reveal a two-domain binding mechanism characteristic of class B GPCRs, in which the C-terminal portion of glucagon engages the receptor extracellular domain while the N-terminal residues insert into the transmembrane core to trigger signaling.

3. Mechanism of Action

Glucagon Receptor and Signaling Cascade

The glucagon receptor (GCGR) is a 485-amino acid class B (secretin family) G-protein-coupled receptor expressed predominantly in the liver, with lower expression in the kidney, heart, adipose tissue, brain, adrenal glands, and gastrointestinal smooth muscle [4][7].

Upon glucagon binding, the GCGR undergoes a conformational change that activates the stimulatory G-protein (Gsalpha), which in turn activates adenylyl cyclase to produce cyclic AMP (cAMP) from ATP [4][5]. The resulting rise in intracellular cAMP activates protein kinase A (PKA), initiating a phosphorylation cascade:

1. Glycogenolysis activation. PKA phosphorylates phosphorylase kinase (PhK), converting it to its active form. Active PhK in turn phosphorylates glycogen phosphorylase b to its active a form, which catalyzes the sequential release of glucose-1-phosphate residues from glycogen. This is the most rapid mechanism by which glucagon raises blood glucose, with effects detectable within minutes [4][5].

2. Glycogen synthesis inhibition. PKA simultaneously phosphorylates glycogen synthase, shifting it from the active (a) to inactive (b) form, thereby preventing futile cycling between glycogen synthesis and breakdown [4].

3. Gluconeogenesis stimulation. PKA phosphorylates the transcription factor CREB (cAMP response element-binding protein), which translocates to the nucleus and upregulates expression of PGC-1alpha (peroxisome proliferator-activated receptor gamma coactivator 1-alpha). PGC-1alpha subsequently drives transcription of the gluconeogenic enzymes phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) [4][5]. This transcriptional program accounts for the sustained glucose-raising effect of glucagon over hours.

4. Glycolysis suppression. Glucagon signaling reduces levels of fructose-2,6-bisphosphate (a potent allosteric activator of phosphofructokinase-1) by promoting PKA-mediated phosphorylation of the bifunctional enzyme PFK-2/FBPase-2, shifting its activity toward the phosphatase function. This effectively diverts carbon flux from glycolysis toward gluconeogenesis [4][5].

Secondary Signaling Pathways

In addition to the canonical Gs-cAMP-PKA axis, GCGR activation also engages the Gq/phospholipase C/inositol trisphosphate (IP3) pathway in certain tissues, leading to calcium release from the endoplasmic reticulum [6]. GCGR has also been shown to recruit beta-arrestin 1, as captured in cryo-EM structures, which may mediate receptor desensitization and internalization [7].

Cardiac Effects

Glucagon exerts positive inotropic and chronotropic effects on the myocardium by activating adenylyl cyclase in cardiomyocytes through a mechanism that bypasses the beta-adrenergic receptor. This property is the basis for its use in beta-blocker and calcium channel blocker poisoning, as glucagon can increase heart rate, cardiac contractility, and atrioventricular conduction even in the presence of complete beta-receptor blockade [9][10].

Gastrointestinal Effects

Glucagon relaxes gastrointestinal smooth muscle, reducing motility of the stomach, duodenum, small bowel, and colon. It also decreases lower esophageal sphincter tone. These effects are exploited diagnostically to reduce motion artifact during radiologic imaging procedures [20].

4. Physiological Role

Glucagon is the primary hormonal defense against hypoglycemia and the major counter-regulatory hormone to insulin [3][21]. The insulin-to-glucagon molar ratio in the portal vein is a key determinant of hepatic glucose output.

Fasting state. As blood glucose declines between meals and during overnight fasting, glucagon secretion from alpha cells increases while insulin secretion decreases. The resulting shift in the portal insulin-to-glucagon ratio promotes hepatic glycogenolysis (consuming glycogen stores within 12–24 hours) and gluconeogenesis (sustaining glucose production during prolonged fasting) [3][5].

Fed state. After a meal, rising glucose and insulin suppress glucagon secretion, reducing hepatic glucose output and favoring glycogen storage.

Counter-regulation during hypoglycemia. When blood glucose falls below approximately 65–70 mg/dL, glucagon release is rapidly stimulated as the first-line counter-regulatory response. In patients with type 1 diabetes, this glucagon counter-regulatory response is often impaired within the first few years of disease, dramatically increasing the risk of severe hypoglycemia [21].

Amino acid metabolism. Glucagon plays an essential role in the liver-alpha cell axis, a feedback loop in which circulating amino acids stimulate glucagon secretion and glucagon promotes hepatic amino acid catabolism and ureagenesis. Disruption of this axis may contribute to the hyperaminoacidemia and alpha-cell hyperplasia observed in glucagon receptor knockout models [22].

Lipid metabolism. Glucagon promotes hepatic fatty acid oxidation and ketogenesis while inhibiting lipogenesis. These effects contribute to the rationale for incorporating glucagon receptor agonism into multi-agonist therapies for obesity and metabolic dysfunction-associated steatohepatitis (MASH) [6][16][17].

5. Clinical Applications

Severe Hypoglycemia Rescue (FDA-Approved)

The primary clinical indication for glucagon is the emergency treatment of severe hypoglycemia in patients with diabetes who are unable to take oral carbohydrates. Severe hypoglycemia can cause loss of consciousness, seizures, and death if untreated [20].

Standard dosing. For adults and children weighing 25 kg or more, the dose is 1 mg administered by intramuscular (IM), subcutaneous (SC), or intravenous (IV) injection. For children weighing <25 kg, the dose is 0.5 mg. Onset of blood glucose elevation occurs within 5–20 minutes depending on route, with peak effect at 30–60 minutes [20].

Comparison with IV dextrose. In hospital settings, IV dextrose (D50W for adults, D25W or D10W for pediatric patients) is typically preferred when IV access is available because it raises blood glucose faster and more predictably than glucagon. Glucagon requires adequate hepatic glycogen stores to be effective and may fail in malnourished patients, those with chronic liver disease, adrenal insufficiency, or prolonged fasting states. However, glucagon's advantage lies in its ability to be administered by non-medical personnel via IM/SC injection or nasal inhalation when IV access is unavailable [20].

Beta-Blocker Overdose (Off-Label)

Glucagon is considered a first-line antidote for hemodynamically significant beta-blocker toxicity, based on its ability to increase cAMP in cardiomyocytes independently of the beta-adrenergic receptor [9][10]. The recommended dose is 3–10 mg IV bolus (approximately 50–150 mcg/kg) administered over 1–5 minutes, followed by a continuous infusion of the effective bolus dose per hour (typically 1–5 mg/hour). Onset of hemodynamic improvement occurs within 1–3 minutes of IV administration. The evidence base consists primarily of case reports, case series, and animal studies; no randomized controlled trials have been performed [10].

Calcium Channel Blocker Overdose (Off-Label)

Glucagon may be used as adjunctive therapy in calcium channel blocker toxicity, although the evidence is weaker than for beta-blocker overdose. High-dose insulin-euglycemia therapy (HIE) has largely supplanted glucagon as the primary pharmacologic intervention for severe CCB poisoning. When used, glucagon dosing follows the same protocol as for beta-blocker overdose [10][20].

Diagnostic Aid for Gastrointestinal Imaging (FDA-Approved)

Glucagon is approved as a GI motility inhibitor during radiologic examinations. By relaxing gastrointestinal smooth muscle, it reduces peristaltic artifact during upper GI series, barium enema, CT enterography, and MR enterography [20]:

• Stomach and small bowel: 0.2–0.5 mg IV or 1 mg IM.
• Colon: 0.5–0.75 mg IV or 1–2 mg IM.
• Duration of GI relaxation is approximately 9–25 minutes after IV administration and 12–32 minutes after IM.

Esophageal Food Bolus Impaction (Off-Label, Limited Evidence)

Although historically used at doses of 1–2 mg IV for esophageal food bolus impaction, a 2019 systematic review and meta-analysis found that glucagon was no more effective than placebo (success rate approximately 30% in both groups) and was associated with more adverse events, particularly vomiting [20]. Current guidelines favor early endoscopic intervention rather than pharmacologic management.

Other Investigational and Historical Uses

Glucagon has been studied as a cardiac stress agent (as an alternative to dobutamine in patients who cannot receive catecholamines), and it was historically used in anaphylaxis refractory to epinephrine in patients on beta-blockers, though evidence for the latter is anecdotal [20].

6. Pharmaceutical Formulations

Traditional Formulations

• Glucagon Emergency Kit (Eli Lilly) — Lyophilized glucagon 1 mg vial with diluent for reconstitution; approved 1998, discontinued December 2022.
• GlucaGen HypoKit (Novo Nordisk) — Lyophilized glucagon 1 mg kit with diluent; approved 1998, remains available.

Both traditional kits require multi-step reconstitution (inject diluent into powder vial, swirl, withdraw, inject), which has been shown to be error-prone under the stress of a hypoglycemic emergency.

Next-Generation Formulations

• Baqsimi (Eli Lilly) — Intranasal glucagon 3 mg dry powder in a single-use device, FDA-approved July 2019. The first needle-free glucagon product. Does not require inhalation; the device delivers glucagon to the nasal mucosa upon actuation. Non-inferior to IM glucagon 1 mg for hypoglycemia rescue [11].

• Gvoke / Gvoke HypoPen (Xeris Biopharma) — Ready-to-use liquid glucagon injection available as a prefilled syringe or autoinjector, FDA-approved September 2019. Available in 0.5 mg (pediatric) and 1 mg (adult) doses. Uses a proprietary nonaqueous formulation to maintain glucagon stability in solution for up to 30 months [13][14].

• Zegalogue (Zealand Pharma) — Dasiglucagon 0.6 mg/0.6 mL in a prefilled syringe or autoinjector, FDA-approved March 2021. Dasiglucagon is a glucagon receptor agonist analog with seven amino acid substitutions that confer physicochemical stability while maintaining full receptor agonist activity. It is stable at room temperature for up to 12 months and refrigerated for 36 months [12].

7. Pharmacokinetics by Route

7.1 Comprehensive Route-Dependent PK Comparison

Glucagon's pharmacokinetic profile varies substantially by route of administration, which has direct clinical implications for formulation selection in emergency and diagnostic settings:

| PK Parameter | IV | IM | SC | Intranasal (Baqsimi) | SC -- Dasiglucagon (Zegalogue) | |---|---|---|---|---|---| | Standard dose | 0.5-1 mg | 1 mg | 1 mg | 3 mg nasal powder | 0.6 mg | | Onset (glucose rise) | 5-10 min | 10-20 min | 20-30 min | 10-20 min | 5-10 min | | Time to peak plasma | Immediate (end of injection) | ~10 min | 10-13 min | ~15-20 min | ~35 min | | Cmax (ng/mL) | ~6,000-8,000 (1 mg) | ~2,000-3,000 (1 mg) | ~1,500-2,500 (1 mg) | ~1,200-1,800 (3 mg) | ~1,400 (0.6 mg) | | Time to peak glucose | 5-20 min | ~30 min | 30-45 min | ~40-60 min | ~30 min | | Half-life | 8-18 min | ~26 min | ~42 min | ~35 min | ~0.5 hours | | Duration of glucose effect | 60-90 min | 60-90 min | 60-90 min | 60-90 min | 60-120 min | | Bioavailability | 100% | ~100% | ~100% | ~25-30% (nasal mucosa) | ~100% | | Absorption variability | None (direct vascular) | Low | Moderate | Moderate (nasal congestion can reduce) | Low | | Degradation | Hepatic + renal + plasma proteolysis | Same | Same | Same (after absorption) | Similar (7 amino acid substitutions confer stability) |

7.2 Route Selection Rationale

IV glucagon:

• Fastest onset; preferred in hospital/ED settings when IV access exists
• Used for beta-blocker/CCB overdose (high-dose bolus + infusion)
• Used for GI diagnostic imaging (precise onset and duration)
• Requires healthcare professional for administration

IM glucagon:

• Traditional emergency rescue route for bystander administration
• Reliable absorption even in shock/hypoperfusion (better than SC)
• Requires reconstitution with traditional kits (error-prone under stress)
• Gvoke HypoPen autoinjector eliminates reconstitution step

SC glucagon:

• Slowest onset among injection routes; adequate for non-critical rescue
• Gvoke HypoPen provides ready-to-use SC autoinjection
• Dasiglucagon (Zegalogue) uses SC route with faster onset due to analog stability

Intranasal glucagon (Baqsimi):

• Needle-free; simplest for lay administration
• 3 mg dose compensates for ~25-30% nasal bioavailability
• Time to peak glucose (~60 min) is longer than IM, but glucose recovery by 30 minutes is non-inferior [11]
• Nasal congestion or concurrent rhinitis may reduce absorption (though Phase 3 showed adequate efficacy regardless)
• No reconstitution; single-step nasal device actuation

7.3 Glucagon Formulation Stability Comparison

| Formulation | Storage Stability | Room Temperature Stability | Reconstitution Required | Key Innovation | |---|---|---|---|---| | GlucaGen HypoKit | 36 months (2-8 C) | 18 months (up to 25 C) | Yes (multi-step) | Legacy formulation | | Baqsimi nasal | 36 months (up to 30 C) | Same (no refrigeration needed) | No | Nasal dry powder delivery | | Gvoke (liquid) | 30 months (20-25 C) | Same (room temperature stable) | No | Nonaqueous formulation prevents fibrillation [13] | | Zegalogue (dasiglucagon) | 36 months (2-8 C); 12 months (up to 25 C) | 12 months at room temperature | No | 7 amino acid substitutions prevent aggregation [12] |

The instability of native glucagon in aqueous solution (fibrillation and aggregation within hours at physiological pH) was the central pharmaceutical challenge that necessitated lyophilized formulations for decades. Xeris solved this with a nonaqueous DMSO-based solvent system [13], while Zealand engineered the dasiglucagon analog with substitutions that eliminate the aggregation-prone regions of the native sequence [12].

8. Dose-Response: Hypoglycemia Recovery

8.1 Dose-Response by Indication

| Indication | Dose | Route | Glucose Rise | Time to Recovery (glucose 70+ mg/dL) | Key Data | |---|---|---|---|---|---| | Hypoglycemia rescue (adult) | 1 mg | IM | +80-120 mg/dL | Median 10-15 min | 95-100% recovery by 30 min | | Hypoglycemia rescue (adult) | 1 mg | SC (Gvoke) | +70-110 mg/dL | Median 13-16 min | 99% success [14] | | Hypoglycemia rescue (adult) | 3 mg | Nasal (Baqsimi) | +70-100 mg/dL | Median 16-20 min | 98.8% recovery by 30 min; non-inferior to IM [11] | | Hypoglycemia rescue (adult) | 0.6 mg | SC (dasiglucagon) | +80-115 mg/dL | Median 10 min | Faster median recovery than reconstituted glucagon [12] | | Hypoglycemia rescue (pediatric, 25+ kg) | 1 mg | IM/SC | +80-120 mg/dL | Median 10-15 min | 100% recovery in pediatric Gvoke trial | | Hypoglycemia rescue (pediatric, less than 25 kg) | 0.5 mg | IM/SC | +60-100 mg/dL | Median 12-18 min | Weight-based dosing prevents excessive hyperglycemia | | Beta-blocker overdose | 3-10 mg (50-150 mcg/kg) IV bolus | IV | N/A (cardiac effect) | HR improvement 1-3 min | Followed by 1-5 mg/hr infusion [9][10] | | GI imaging (stomach) | 0.2-0.5 mg | IV | N/A (GI relaxation) | GI relaxation onset ~1 min | Duration 9-25 min | | GI imaging (colon) | 0.5-0.75 mg | IV | N/A (GI relaxation) | GI relaxation onset ~1 min | Duration 12-32 min | | GI imaging | 1-2 mg | IM | N/A (GI relaxation) | GI relaxation onset 8-10 min | Duration 12-32 min |

8.2 Dose-Response Relationship for Glycemic Effect

The glucose-raising effect of glucagon follows a dose-dependent relationship with an upper plateau [20]:

• 0.25 mg IM: Raises blood glucose by ~30-50 mg/dL; may be insufficient for severe hypoglycemia
• 0.5 mg IM: Raises blood glucose by ~50-80 mg/dL; adequate for pediatric patients less than 25 kg
• 1.0 mg IM: Raises blood glucose by ~80-120 mg/dL; standard adult rescue dose
• 2.0 mg IM: Does not produce significantly greater glucose elevation than 1 mg; increases nausea/vomiting
• The dose-response plateaus at ~1 mg because hepatic glycogen mobilization reaches a ceiling; higher doses do not extract more glucose from glycogen stores

For the cardiac indication (beta-blocker overdose), much higher doses are required (3-10 mg IV) because the therapeutic target is direct cardiac cAMP elevation rather than hepatic glycogenolysis, and the cardiac GCGR requires higher concentrations for adequate activation [9][10].

8.3 Factors Affecting Glycemic Response

| Factor | Effect on Glucagon Efficacy | Clinical Implication | |---|---|---| | Hepatic glycogen stores | Depleted glycogen eliminates response | Glucagon fails in fasting, malnutrition, alcoholism | | Alcohol intoxication | Inhibits gluconeogenesis and depletes glycogen | IV dextrose preferred | | Adrenal insufficiency | Impaired counter-regulation | Reduced glucagon response; treat with dextrose + hydrocortisone | | Chronic liver disease | Reduced glycogen storage capacity | Attenuated response; IV dextrose preferred | | Sulfonylurea overdose | Glucagon may transiently raise glucose but stimulates further insulin release | Octreotide preferred as adjunct; glucagon alone may be inadequate | | Insulin overdose (depot) | Ongoing insulin absorption may overcome glucagon effect | Repeat doses or continuous dextrose infusion may be needed | | Neonates | Limited glycogen stores | Glucagon is second-line after IV dextrose (D10W) | | Fed vs fasted state | Fed patients have greater glycogen stores | Better response in recently fed patients |

9. Comparative Effectiveness: Glucagon vs Dextrose vs Dasiglucagon

9.1 Emergency Hypoglycemia Treatment Options

| Feature | IV Dextrose (D50W/D10W) | Glucagon (IM/SC) | Baqsimi (Nasal Glucagon) | Gvoke (Ready-Use SC) | Dasiglucagon (Zegalogue SC) | |---|---|---|---|---|---| | Onset | 1-3 min | 10-20 min | 10-20 min | 10-15 min | 5-10 min | | Median time to recovery | 3-5 min | 10-15 min | 16-20 min | 13-16 min | 10 min | | Success rate by 30 min | ~100% | 95-99% | 98.8% | 99-100% | 99% | | IV access required | Yes | No | No | No | No | | Reconstitution | No (premixed) | Yes (traditional kits) | No | No | No | | Needle required | Yes (IV) | Yes | No | Yes (autoinjector) | Yes (prefilled syringe/autoinjector) | | Ease of lay use | Requires trained personnel | Difficult (reconstitution) | Easiest (single nasal actuation) | Easy (autoinjector) | Easy (autoinjector) | | Glycogen dependent | No | Yes | Yes | Yes | Yes | | Nausea/vomiting | Rare | 25-30% | 25-30% | 25-30% | 25-30% | | Volume overload risk | Yes (50 mL D50W = 25 g glucose) | No | No | No | No | | Room temperature storage | Yes | Varies by kit | Yes (up to 30 C) | Yes (up to 25 C) | Up to 12 months at 25 C | | Cost (approximate) | Very low (~$5-10 per dose) | Moderate (~$100-300) | ~$280-340 per device | ~$250-350 per dose | ~$500-600 per dose |

9.2 Dasiglucagon vs Native Glucagon

Dasiglucagon (Zegalogue) is a glucagon receptor agonist analog with 7 amino acid substitutions engineered for physicochemical stability [12]:

| Feature | Native Glucagon (IM/SC) | Dasiglucagon (Zegalogue) | |---|---|---| | Molecular nature | Native 29-aa peptide | 29-aa analog (7 substitutions) | | Aqueous stability | Fibrillates within hours at neutral pH | Stable in solution for 12+ months at room temperature | | Reconstitution | Required (traditional kits) | Not required (prefilled syringe) | | Median time to glucose recovery | 12 min (Phase 3) | 10 min (Phase 3) [12] | | Dose | 1 mg (IM/SC) | 0.6 mg (SC) | | Pediatric dose | 0.5 mg (less than 25 kg) | 0.3 mg (less than 6 years) | | Receptor | GCGR (native agonist) | GCGR (full agonist, comparable efficacy) | | Nausea | 25-30% | 25-30% (comparable) | | Room temperature storage | Limited to hours (reconstituted) | 12 months |

9.3 Clinical Decision Framework

In-hospital (IV access available):

• IV dextrose (D50W 25-50 mL adults; D10W-D25W pediatric) is first-line
• Glucagon reserved for cases where IV access is delayed or unavailable

Out-of-hospital (trained caregiver):

• Baqsimi nasal glucagon: best for lay caregivers unfamiliar with injections (simplest device)
• Gvoke HypoPen: best for caregivers comfortable with autoinjectors (slightly faster onset than nasal)
• Dasiglucagon: fastest recovery time among non-IV options; higher cost

Out-of-hospital (self-treatment of mild-moderate hypoglycemia):

• Oral glucose (15-20 g fast-acting carbohydrate) is first-line for conscious patients
• Glucagon products reserved for loss of consciousness or inability to swallow

Beta-blocker/CCB overdose:

• IV glucagon (3-10 mg bolus + infusion) remains the only route studied
• No role for nasal or SC formulations in this indication due to dose requirements and need for rapid onset

10. Enhanced Safety Profile

10.1 Adverse Event Comparison by Formulation

| Adverse Event | Reconstituted Glucagon (IM) | Baqsimi (Nasal) | Gvoke (SC) | Dasiglucagon (SC) | |---|---|---|---|---| | Nausea | 25-30% | 25-36% | 25-30% | 25-30% | | Vomiting | 15-20% | 15-25% | 15-20% | 15-20% | | Headache | 15-20% | 18-25% | 15-20% | 15-20% | | Nasal/upper airway irritation | N/A | 10-15% (watery eyes, nasal congestion, sneezing) | N/A | N/A | | Injection site reaction | 5-10% | N/A | 3-8% | 3-8% | | Hyperglycemia (rebound) | Expected (transient) | Expected (transient) | Expected (transient) | Expected (transient) | | Hypokalemia | Rare at rescue doses | Rare | Rare | Rare | | Allergic/hypersensitivity | Rare | Rare | Rare | Rare |

10.2 Special Population Safety

Pregnancy: Glucagon is not expected to cause fetal harm (Category B equivalent). It does not cross the placenta in significant amounts. Use in pregnant patients with severe hypoglycemia is appropriate when the benefit outweighs the negligible risk [20].

Renal/hepatic impairment: No dose adjustment required. Glucagon is degraded by multiple tissues (liver, kidney, plasma). In the emergency setting, organ function does not meaningfully alter the glycemic response [20].

Cardiovascular patients: Glucagon produces transient tachycardia and hypertension, which are generally well-tolerated at rescue doses (1 mg) but may be clinically significant at the higher doses used for beta-blocker overdose (3-10 mg). Patients with pheochromocytoma are at risk of hypertensive crisis due to glucagon-stimulated catecholamine release. Patients with insulinoma may experience paradoxical worsening of hypoglycemia due to glucagon-stimulated insulin release from the tumor [20].

10.3 Post-Rescue Management Protocol

After successful glucagon rescue, the following steps are recommended [20]:

1. Position recovery: Turn unconscious patient to lateral position to prevent aspiration if vomiting occurs (expected in 15-30%)
2. Oral carbohydrates: As soon as the patient regains consciousness, administer oral carbohydrates to replenish hepatic glycogen stores
3. Glucose monitoring: Check blood glucose every 15-30 minutes for 2 hours post-rescue
4. Identify cause: Investigate and address the precipitating cause of hypoglycemia (insulin dose error, missed meal, exercise, etc.)
5. Second dose consideration: If no response within 15 minutes, a second dose may be given, but if the patient remains unresponsive after two doses, IV dextrose should be administered (glucagon failure suggests glycogen depletion)
6. Emergency services: Patients who required glucagon rescue should be evaluated by healthcare professionals, particularly if the cause of hypoglycemia is unclear or if they are on sulfonylureas (prolonged hypoglycemia risk)

11. Safety and Adverse Effects

Common adverse effects. Nausea and vomiting are the most frequent adverse reactions and may occur in up to 30% of patients receiving rescue doses. These effects are generally transient and self-limiting [20].

Cardiovascular effects. Transient increases in heart rate and blood pressure may occur, particularly at higher doses used in poisoning management. Hypotension has been reported rarely.

Metabolic effects. Hyperglycemia is expected and desired in the rescue setting. Hypokalemia may occur with large or repeated doses and should be monitored in the toxicology context [9][10].

Allergic reactions. Hypersensitivity reactions including urticaria, respiratory distress, and anaphylaxis have been reported rarely. Patients with known glucagon allergy or allergies to lactose (present in some formulations as an excipient) should be treated with IV dextrose instead.

Contraindications

• Pheochromocytoma. Glucagon may stimulate catecholamine release from the tumor, precipitating a hypertensive crisis.
• Insulinoma. Glucagon may provoke a rebound surge of insulin secretion from the tumor, paradoxically worsening hypoglycemia.
• Glycogen depletion. While not a formal contraindication, glucagon is ineffective in patients with depleted hepatic glycogen stores (starvation, chronic alcoholism, adrenal insufficiency, chronic hypoglycemia), and IV glucose should be administered instead [20].

12. Glucagon in Drug Development: Dual and Triple Agonists

The recognition that glucagon receptor agonism can promote weight loss (through increased energy expenditure, hepatic fat oxidation, and satiety) has fueled intense interest in multi-receptor agonists that combine GLP-1 receptor and glucagon receptor activity [6][25].

Survodutide (BI 456906, Boehringer Ingelheim / Zealand Pharma)

Survodutide is a once-weekly subcutaneous GLP-1/glucagon receptor dual agonist developed by Boehringer Ingelheim and Zealand Pharma, currently in Phase 3 development. In a Phase 2 dose-finding trial for obesity, survodutide produced dose-dependent weight loss of up to 14.9% at 46 weeks (4.8 mg dose) versus 2.8% with placebo [16]. A Phase 2 trial in MASH, published in the New England Journal of Medicine in 2024, demonstrated resolution of steatohepatitis without worsening fibrosis in up to 62% of patients at the 4.8 mg dose versus 14% with placebo [17]. The Phase 3 SYNCHRONIZE program is now fully enrolled: SYNCHRONIZE-1 (obesity without T2D) and SYNCHRONIZE-2 (obesity with T2D) have published baseline characteristics in early 2026, with primary efficacy results (percent change in body weight and achievement of 5% or greater weight loss at Week 76) expected in H1 2026 [24]. Survodutide has also received FDA Breakthrough Therapy Designation for MASH, with the LIVERAGE Phase 3 program ongoing, and a cardiovascular outcomes trial (SYNCHRONIZE-CVOT) has been initiated.

Cotadutide (MEDI0382, AstraZeneca)

Cotadutide is a balanced GLP-1/glucagon receptor dual agonist evaluated in phase 2 trials for type 2 diabetes and MASH. It has shown improvements in glycemic control, body weight, and hepatic fat content [18]. Development status is ongoing.

Triple Agonists (GLP-1/GIP/Glucagon)

Several pharmaceutical programs are developing triple agonists that engage the GLP-1, GIP, and glucagon receptors simultaneously, aiming to maximize weight loss and metabolic benefit. The rationale combines the glucose-lowering and appetite-suppressing effects of GLP-1 agonism with the insulinotropic activity of GIP agonism and the energy expenditure and lipid oxidation effects of glucagon agonism [15][25].

Glucagon Receptor Antagonists

Conversely, glucagon receptor antagonists (e.g., LY2409021) have been investigated for type 2 diabetes on the premise that blocking glucagon action would reduce hepatic glucose output. While effective at lowering blood glucose, these agents have been associated with alpha-cell hyperplasia, increases in LDL cholesterol, and elevations in transaminases, limiting their clinical development [23].

13. Clinical Evidence Summary

14. Dosing in Research and Practice

15. Regulatory Status

United States (FDA). Glucagon injection has been approved since 1960 for the treatment of severe hypoglycemia and as a diagnostic aid for GI radiologic examinations. Current approved products include GlucaGen (Novo Nordisk), Baqsimi (Eli Lilly, 2019), Gvoke/Gvoke HypoPen (Xeris Biopharma, 2019), and Zegalogue (Zealand Pharma, 2021) [11][12][14][20].

European Union (EMA). GlucaGen (Novo Nordisk) and Baqsimi (Eli Lilly) are approved. Ogluo (dasiglucagon, Zealand Pharma) received EMA marketing authorization.

Off-label uses. Beta-blocker overdose, calcium channel blocker overdose, and esophageal food bolus impaction remain off-label indications with varying levels of evidence [9][10][20].

16. Related Peptides

See also: Semaglutide, Liraglutide, Exenatide, Tirzepatide, Amylin, Secretin, VIP

17. References

1. [1] Kimball CP, Murlin JR. (1923). Aqueous extracts of pancreas. III. Some precipitation reactions of insulin. Journal of Biological Chemistry. DOI PubMed
2. [2] Bromer WW, Sinn LG, Staub A, Behrens OK. (1957). The amino acid sequence of glucagon. Journal of the American Chemical Society. DOI PubMed
3. [3] Habegger KM, Heppner KM, Geary N, et al. (2010). The metabolic actions of glucagon revisited. Nature Reviews Endocrinology. DOI PubMed
4. [4] Jiang G, Zhang BB. (2003). Glucagon and regulation of glucose metabolism. American Journal of Physiology-Endocrinology and Metabolism. DOI PubMed
5. [5] Ramnanan CJ, Edgerton DS, Kraft G, Cherrington AD. (2011). Physiologic action of glucagon on liver glucose metabolism. Diabetes, Obesity and Metabolism. DOI PubMed
6. [6] Muller TD, Finan B, Clemmensen C, DiMarchi RD, Tschop MH. (2017). The new biology and pharmacology of glucagon. Physiological Reviews. DOI PubMed
7. [7] Qiao A, Han S, Li X, et al. (2020). Structural basis of Gs and Gi recognition by the human glucagon receptor. Science. DOI PubMed
8. [8] Zhang H, Qiao A, Yang D, et al. (2017). Structure of the full-length glucagon class B G-protein-coupled receptor. Nature. DOI PubMed
9. [9] Peterson CD, Leeder JS, Sterner S. (1984). Glucagon therapy for beta-blocker overdose. Drug Intelligence and Clinical Pharmacy. DOI PubMed
10. [10] Bailey B. (2003). Glucagon in beta-blocker and calcium channel blocker overdoses: a systematic review. Journal of Toxicology - Clinical Toxicology. DOI PubMed
11. [11] Rickels MR, Ruedy KJ, Foster NC, et al. (2016). Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: a randomized crossover noninferiority study. Diabetes Care. DOI PubMed
12. [12] Pieber TR, Aronson R, Gal P, et al. (2021). Dasiglucagon - a next-generation glucagon analog for rapid and effective treatment of severe hypoglycemia: results of phase 3 randomized double-blind clinical trial. Diabetes Care. DOI PubMed
13. [13] Newswanger B, Ammons S, Phadnis N, et al. (2015). Development of a highly stable, nonaqueous glucagon formulation for delivery via infusion pump systems. Journal of Diabetes Science and Technology. DOI PubMed
14. [14] Valentine V, Newswanger B, Prestrelski S, Andre AD, Garibaldi M. (2019). Human factors usability and validation studies of a glucagon autoinjector and a prefilled syringe with stable liquid glucagon in a simulated severe hypoglycemia rescue. Diabetes Technology and Therapeutics. DOI PubMed
15. [15] Bossart M, Wagner M, Elvert R, et al. (2022). Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. Cell Metabolism. DOI PubMed
16. [16] Nahra R, Wang T, Gadde KM, et al. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes and Endocrinology. DOI PubMed
17. [17] Sanyal AJ, Bedossa P, Engel SS, et al. (2024). A phase 2 randomized trial of survodutide in MASH and fibrosis. New England Journal of Medicine. DOI PubMed
18. [18] Parker VER, Robertson D, Wang T, et al. (2020). Efficacy, safety, and mechanistic insights of cotadutide, a dual receptor GLP-1 and glucagon agonist. Journal of Clinical Endocrinology and Metabolism. DOI PubMed
19. [19] Buse JB, Wexler DJ, Tsapas A, et al. (2020). 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the ADA and the EASD. Diabetes Care. DOI PubMed
20. [20] Glucagon - StatPearls (2024). Glucagon. StatPearls [Internet], Treasure Island (FL). DOI PubMed
21. [21] Unger RH, Cherrington AD. (2012). Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. Journal of Clinical Investigation. DOI PubMed
22. [22] Holst JJ, Wewer Albrechtsen NJ, Pedersen J, Knop FK. (2017). Glucagon and amino acids are linked in a mutual feedback cycle: the liver-alpha-cell axis. Diabetes. DOI PubMed
23. [23] Kazda CM, Ding Y, Kelly RP, et al. (2016). Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes. Diabetes Care. DOI PubMed
24. [24] Wharton S, Blevins T, Engel SS, et al. (2026). Baseline characteristics in the SYNCHRONIZE-2 randomized phase 3 trial of survodutide for obesity in people with type 2 diabetes. Diabetes, Obesity and Metabolism. DOI PubMed
25. [25] Capozzi ME, DiMarchi RD, Tschop MH, Finan B, Campbell JE. (2018). Targeting the incretin/glucagon system with triagonists to treat diabetes. Endocrine Reviews. DOI PubMed